The themes Johnson & Johnson is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Di InspectStocks · 20 companies
Surgical robots, implants, heart devices, glucose monitors and other medical equipment.
A 8B 7C 3D 2
Di InspectStocks · 13 companies
The largest drugmakers, selling prescription medicines worldwide.
A 7B 3C 3
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Le quote di ricavo sono stime per six months ended June 28, 2026, high confidence, non cifre tratte da un documento depositato.
DARZALEX
A medicine used to treat multiple myeloma, a cancer of plasma cells.
TREMFYA
A medicine for conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
CARVYKTI
A treatment made from a patient’s modified immune cells for multiple myeloma that has returned or has not responded to earlier treatment.
VARIPULSE
A system that uses pulsed electrical energy to treat atrial fibrillation, a disorder that causes an irregular heartbeat.
Impella
A heart pump used to support blood circulation in certain patients with heart failure or during high-risk heart procedures.
ACUVUE
A brand of contact lenses sold for vision correction.
Johnson & Johnson develops, makes and sells prescription medicines and medical devices around the world. Its two businesses are Innovative Medicine, which sells medicines for conditions including cancer and immune disorders, and MedTech, which sells products used in heart procedures, surgery, orthopaedics and vision care.
Costruito dai documenti depositati da Johnson & Johnson presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
286,06 USD+0,9%chiusura 13 nov
Dati fino al 27 settembre 2026, dal 10-Q depositato il 21 ottobre 2026
Makes prescription medicines and medical devices for cancer, immune disorders, surgery, heart care, joint replacement and vision.
Grade A+
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 41 dello storico dei voti di Johnson & Johnson. Gli altri 39 risalgono fino a novembre 2016.